GLP1R and metabolic dysfunction-associated steatotic liver disease: The results of clinical trials evaluating GLP-1 analogs for the treatment of NAFLD are expected in the near future, and the feasibility of using oral drugs, in addition to injectable drugs, is also being evaluated.